Generation of microglia from peripheral blood mononuclear cells (PBMCs)

Session Number

MEDH 38

Advisor(s)

Dr. Jennillee Wallace, RUSH University

Discipline

Medical and Health Sciences

Start Date

17-4-2025 10:45 AM

End Date

17-4-2025 11:00 AM

Abstract

Microglia are resident brain macrophages that modulate the release of cytokines to mediate neuroinflammation. Conversely, they may release inflammatory mediators that promote protein aggregation and neuronal damage in neurodegenerative diseases. Furthermore, challenges with obtaining mature microglia reprogrammed from inducible pluripotent stem cells (iPSCs) hinder the ability to accurately understand their role in neurodegenerative diseases in vitro. Our objective, therefore, is to derive phenotypically mature and biologically relevant microglia derived from PBMCs. For the methodology, PBMCs were reprogrammed to microglia using IL-34 and GM-CSF for 2 weeks. We were able to successfully obtain morphologically representative microglia. To further verify the phenotype of the obtained microglia, we performed a flow cytometry where cells expressed Iba1, CD11b, and had no CD45, which is reminiscent of microglia in vivo. Ongoing and future studies will assess the effect of HIV and antiretroviral therapy on resident brain myeloid cells such as microglia an macrophages.

Share

COinS
 
Apr 17th, 10:45 AM Apr 17th, 11:00 AM

Generation of microglia from peripheral blood mononuclear cells (PBMCs)

Microglia are resident brain macrophages that modulate the release of cytokines to mediate neuroinflammation. Conversely, they may release inflammatory mediators that promote protein aggregation and neuronal damage in neurodegenerative diseases. Furthermore, challenges with obtaining mature microglia reprogrammed from inducible pluripotent stem cells (iPSCs) hinder the ability to accurately understand their role in neurodegenerative diseases in vitro. Our objective, therefore, is to derive phenotypically mature and biologically relevant microglia derived from PBMCs. For the methodology, PBMCs were reprogrammed to microglia using IL-34 and GM-CSF for 2 weeks. We were able to successfully obtain morphologically representative microglia. To further verify the phenotype of the obtained microglia, we performed a flow cytometry where cells expressed Iba1, CD11b, and had no CD45, which is reminiscent of microglia in vivo. Ongoing and future studies will assess the effect of HIV and antiretroviral therapy on resident brain myeloid cells such as microglia an macrophages.